Black patients with psoriasis had the lowest rate of switching to another biologic therapy compared with other racial and ethnic groups, suggesting possible disparities in treatment patterns.
Female sex, hyperlipidemia, Medicaid insurance, earlier year of biologic initiation, shorter duration of psoriasis, and prior nonbiologic systemic therapy use were associated with multiple biologic failure.